Want to see APGE full AI Analyst Report?
Top Page
Apogee Therapeutics
(NASDAQ:APGE)
Select Model
Select Model
Rating:64Neutral
Price Target:
$144.00
▲(6.79% Upside)
Action:Reiterated
Date:08/17/26
The score is supported most by a strong capital position (very low leverage) and major positive corporate catalysts (approved AbbVie acquisition and other favorable milestones). Offsetting this, the underlying operating profile remains weak with minimal revenue and heavy ongoing cash burn, and technically the stock looks overbought (RSI > 70) despite a clear uptrend.
Positive Factors
Strong balance sheet
Minimal leverage and a sizable capital base provide flexibility to fund clinical development, absorb setbacks, and pursue strategic opportunities without immediate dependence on equity financing.
Negative Factors
Pre-commercial revenue profile
The company has not established a meaningful revenue stream or operating leverage, leaving its long-term economics dependent on successful clinical development, regulatory approval, and eventual product launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Minimal leverage and a sizable capital base provide flexibility to fund clinical development, absorb setbacks, and pursue strategic opportunities without immediate dependence on equity financing.
Read all positive factors
Apogee Therapeutics (APGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.21B
Dividend YieldN/A
Average Volume (3M)4.35M
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue GrowthN/A
EPS Growth-6.36%
CountryUS
Employees261
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.34
Shares Outstanding62,201,090
10 Day Avg. Volume1,022,216
30 Day Avg. Volume4,345,940
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$131.18Price Target Upside-2.72% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-4.54
Revenue Forecast (FY)N/A
Apogee Therapeutics Business Overview & Revenue Model
Company Description
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammat...
How the Company Makes Money
null...
Apogee Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -408.00K | -1.42M | 0.00 | 0.00 | 0.00 |
| EBITDA | -291.30M | -254.15M | -181.94M | -74.97M | -39.78M |
| Net Income | -294.37M | -255.84M | -182.15M | -83.98M | -39.78M |
Balance Sheet | |||||
| Total Assets | 1.34B | 937.13M | 753.95M | 401.40M | 152.06M |
| Cash, Cash Equivalents and Short-Term Investments | 971.93M | 730.19M | 520.65M | 395.46M | 151.89M |
| Total Debt | 6.83M | 8.85M | 11.83M | 2.03M | 0.00 |
| Total Liabilities | 141.21M | 33.25M | 37.16M | 21.49M | 9.98M |
| Stockholders Equity | 1.19B | 903.88M | 716.79M | 379.91M | 142.07M |
Cash Flow | |||||
| Free Cash Flow | -243.96M | -232.60M | -172.33M | -74.93M | -16.43M |
| Operating Cash Flow | -243.89M | -227.45M | -171.17M | -74.76M | -16.43M |
| Investing Cash Flow | -687.89M | -179.57M | -300.46M | -273.91M | 0.00 |
| Financing Cash Flow | 912.87M | 396.49M | 495.11M | 315.39M | 168.32M |
Apogee Therapeutics Technical Analysis
Positive
134.85
Price Trends
131.22
Positive
107.85
Positive
90.10
Positive
Market Momentum
1.52
Positive
78.09
Negative
89.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APGE, the sentiment is Positive. The current price of 134.85 is above the 20-day moving average (MA) of 134.56, above the 50-day MA of 131.22, and above the 200-day MA of 90.10, indicating a bullish trend. The MACD of 1.52 indicates Positive momentum. The RSI at 78.09 is Negative, neither overbought nor oversold. The STOCH value of 89.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APGE.
Apogee Therapeutics Risk Analysis
Apogee Therapeutics disclosed 77 risk factors in its most recent earnings report. Apogee Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Apogee Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $10.21B | -31.10 | -29.88% | ― | ― | -6.36% | |
62 Neutral | $6.39B | 44.57 | 149.64% | ― | 2233.65% | ― | |
59 Neutral | $4.01B | -21.76 | -16.47% | ― | 3244.67% | 49.14% | |
55 Neutral | $2.03B | -4.89 | -35.67% | ― | 140.58% | -161.11% | |
52 Neutral | $2.37B | -7.62 | -59.87% | ― | -8.14% | -10.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
APGE
Apogee Therapeutics
134.96
98.34
268.54%
AGIO
Agios Pharma
34.28
-3.90
-10.21%
OCUL
Ocular Therapeutix
10.82
-1.70
-13.58%
LQDA
Liquidia Technologies
69.94
42.48
154.70%
IDYA
IDEAYA Biosciences
41.77
16.84
67.55%
Apogee Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsShareholder Meetings
Apogee Shareholders Approve AbbVie Acquisition and Leadership Transition
Positive
Aug 11, 2026
On August 11, 2026, Apogee Therapeutics held a virtual special meeting of stockholders to vote on its previously announced merger agreement with AbbVie’s subsidiary, Andor LLC, under which Apogee will survive as an indirect wholly owned subs...
Business Operations and StrategyM&A Transactions
Apogee Therapeutics to Be Acquired by AbbVie
Positive
Jun 22, 2026
On June 18, 2026, Apogee Therapeutics agreed to be acquired by AbbVie under a merger deal that will see Apogee become a wholly owned subsidiary of an AbbVie-controlled parent, with shareholders receiving $135.11 per share in cash, valuing the comp...
Business Operations and Strategy
Apogee, Paragon Partner on IL-31R Antibody Program
Positive
Jun 22, 2026
On June 17, 2026, Apogee Therapeutics, Inc. entered an IL-31R antibody discovery agreement with Paragon Therapeutics, under which Paragon will generate and characterize monospecific antibodies against interleukin 31 receptor and may perform option...
Executive/Board ChangesShareholder Meetings
Apogee Therapeutics Shareholders Back Board, Auditors, Compensation
Positive
Jun 12, 2026
On June 9, 2026, Apogee Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, with 61,853,254 shares of voting common stock eligible to participate as of the April 15, 2026 record date. Stockholders elected Class III directors Mark C. M...
Business Operations and StrategyProduct-Related Announcements
Apogee Advances Zumilokibart After Positive Phase 2 Results
Positive
May 27, 2026
On May 27, 2026, Apogee Therapeutics reported that Part B of its Phase 2 APEX trial in moderate-to-severe atopic dermatitis met all primary and key secondary endpoints, with mid-dose zumilokibart achieving an EASI-75 response in 65.9% of patients ...
Business Operations and StrategyPrivate Placements and Financing
Apogee Therapeutics Secures Major Non-Dilutive Blackstone Financing
Positive
May 27, 2026
On May 26, 2026, Apogee Therapeutics entered a revenue participation agreement with Blackstone Life Sciences affiliate Annapurna Aggregator L.P., securing an initial $100 million synthetic royalty tranche tied to future global sales of its anti-IL...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.